This proof-of-concept study also verified the value of the bsAb-based immunotherapy to leverage the potent anti-tumor capacity of Vγ2Vδ2 T cells, and suggested that the combination of the Vγ2Vδ2 T cells and Y111 could be applied for PD-L1+ cancer therapies. The gene discussed is CD274; the disease is neoplasm.